Lonza Group AG 2020 AR2
The report highlights Lonza's financial and operational performance for the fiscal year 2020, during which the company achieved CHF 4.5 billion in sales and 12% sales growth in constant currency. Lonza played a critical role in the fight against the COVID-19 pandemic, notably partnering with Moderna to manufacture the drug substance for its vaccine. The company also announced the decision to divest its Specialty Ingredients segment to focus on its core Pharma Biotech & Nutrition business. Additionally, Lonza continued its commitment to sustainability by tracking its 2030 environmental targets and addressing nitrous oxide emissions at its Visp site.
Company: Lonza Group AG
Sector: Manufacturing
Country: Switzerland
Year: 2020
Type: AR2
Pages: 244
Back to company
Lonza Group AG
Annual Report
The report highlights Lonza's financial and operational performance for the fiscal year 2020, during which the company achieved CHF 4.5 billion in sales and 12% sales growth in constant currency. Lonza played a critical role in the fight against the COVID-19 pandemic, notably partnering with Moderna to manufacture the drug substance for its vaccine. The company also announced the decision to divest its Specialty Ingredients segment to focus on its core Pharma Biotech & Nutrition business. Additionally, Lonza continued its commitment to sustainability by tracking its 2030 environmental targets and addressing nitrous oxide emissions at its Visp site.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2020
Reporting Period
Jan 1, 2020 - Dec 31, 2020
Fiscal Year
2020
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Women on Board
Women in Management
Employees